Oruka Therapeutics Inc. held its Annual Meeting of Stockholders on June 2, 2025. During the meeting, stockholders elected two Class I directors, Carl Dambkowski and Peter Harwin. The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. Stockholders also approved a one-year frequency for future advisory votes on executive compensation.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-050756), on June 03, 2025, and is solely responsible for the information contained therein.